Ignite Creation Date:
2024-05-05 @ 11:19 AM
Last Modification Date:
2024-10-26 @ 9:02 AM
Study NCT ID:
NCT00002080
Status:
COMPLETED
Last Update Posted:
2005-06-24
First Post:
1999-11-02
Brief Title:
Rifabutin Therapy for the Prevention of Mycobacterium Avium Complex MAC Bacteremia in HIV Positive Patients With CD4 Counts or 200 Treatment IND Study
Sponsor:
Pharmacia
Organization:
NIH AIDS Clinical Trials Information Service
Study Overview
Official Title:
Rifabutin Therapy for the Prevention of Mycobacterium Avium Complex MAC Bacteremia in HIV Positive Patients With CD4 Counts or 200 Treatment IND Study
Status:
COMPLETED
Status Verified Date:
2003-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Primary To provide rifabutin to HIV positive patients in an attempt to prevent or delay Mycobacterium avium Complex MAC infection by a daily dose of rifabutin
Secondary To further characterize the safety of rifabutin monotherapy in preventing or delaying MAC bacteremia in HIV positive patients with CD4 counts or 200
Secondary To further characterize the safety of rifabutin monotherapy in preventing or delaying MAC bacteremia in HIV positive patients with CD4 counts or 200
Detailed Description:
None
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?:
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 087085-999 | None | None | None |